https://www.selleckchem.com/pr....oducts/anlotinib-al3
d values. Although default values are generally deemed acceptable by regulatory agencies, use of risk/hazard estimates based on these default values may compel insufficiently justified remedial action in some instances. BCKGROUND AIMS Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), hypothesized to treat non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and stimulating hepaticbile acid production. METHODS Adults with ≥5% steatosis and NASH without cirrhosis (N = 197)
Like
Comment
Share
